International Journal of Glaucoma
Publishing groundbreaking research in glaucoma pathophysiology, intraocular pressure management, optic nerve neuroprotection, visual field preservation, and innovative diagnostic technologies enabling earlier detection before irreversible vision loss occurs in patients worldwide.
Join a dedicated global community of ophthalmologists, vision scientists, pharmaceutical researchers, and medical device engineers transforming glaucoma treatment and improving patient outcomes through evidence-based practice and technological innovation advancing clinical care globally.
Bridging Science and Clinical Practice
The International Journal of Glaucoma serves as the premier platform for disseminating cutting-edge research that advances our understanding of glaucoma mechanisms and improves patient care globally through rigorous peer review and open access scholarly communication reaching clinicians, researchers, and public health professionals implementing evidence-based protocols.
Comprehensive Research Scope
We publish comprehensive investigations spanning basic science research examining retinal ganglion cell degeneration mechanisms and trabecular meshwork dysfunction, advanced imaging technologies quantifying structural damage through optical coherence tomography measuring retinal nerve fiber layer thickness and ganglion cell complex thinning, functional assessment methodologies detecting visual dysfunction including standard automated perimetry and newer technologies, randomized controlled clinical trials comparing medical surgical and laser treatment efficacy in pressure reduction and visual field preservation, and health services research examining screening program cost-effectiveness and medication adherence barriers affecting real-world treatment outcomes.
Editorial Excellence
Our international editorial board comprises glaucoma fellowship-trained ophthalmologists with extensive clinical and surgical experience, vision science researchers with expertise in retinal neurodegeneration and intraocular pressure regulation, biostatisticians expert in longitudinal visual field analysis methods and progression detection algorithms, and public health ophthalmologists committed to reducing global blindness burden through early case detection and optimal treatment strategies ensuring the highest scientific standards and clinical relevance.
Global Impact
Glaucoma represents the leading cause of irreversible blindness worldwide affecting over seventy million people with projections reaching one hundred twelve million by 2040 due to population aging and increasing prevalence in high-risk ethnic populations. Our research enables early detection through population screening programs, optimal treatment selection guided by clinical trial evidence, surgical innovation improving outcomes with minimally invasive techniques, and health policy development ensuring access to vision-preserving care preventing blindness globally.
Research Focus Areas
Early Detection Strategies
Population screening approaches balancing sensitivity and specificity, risk stratification algorithms incorporating family history African ancestry and high myopia, anterior segment OCT identifying narrow angles predisposing to angle closure, baseline optic nerve photography, and automated screening technologies including AI-assisted optic disc analysis enabling community-based case-finding programs.
Pressure Management
Intraocular pressure reduction through topical prostaglandin analogs including latanoprost and travoprost enhancing uveoscleral outflow, combination therapy with beta-blockers reducing aqueous production, sustained-release drug delivery systems improving adherence, selective laser trabeculoplasty, and individualized target pressure optimization based on baseline damage severity.
Surgical Innovation
Traditional filtering surgery including trabeculectomy and tube shunt implantation alongside minimally invasive glaucoma surgery including trabecular micro-bypass stents inserted via ab interno approach, canaloplasty dilating Schlemm canal, endocyclophotocoagulation reducing aqueous production, and suprachoroidal shunt placement with improved safety profiles.
Neuroprotection Research
Retinal ganglion cell preservation through neurotrophic factor supplementation including brain-derived neurotrophic factor promoting neuronal survival, mitochondrial dysfunction targeting reducing oxidative stress, glutamate excitotoxicity blockade via NMDA receptor antagonists, neuroinflammation modulation, and gene therapy correcting genetic mutations in familial glaucoma.
Diagnostic Advancement
Swept-source OCT with deeper tissue penetration for enhanced optic nerve head visualization, OCT angiography quantifying peripapillary vessel density reductions correlating with visual field loss, anterior segment OCT measuring angle parameters, multispectral imaging detecting metabolic changes preceding structural damage, and machine learning algorithms integrating multiple diagnostic parameters.
Patient Quality of Life
Treatment burden assessment from multiple daily eyedrops, mobility limitations from peripheral vision loss increasing fall risk, driving difficulties particularly at night, medication side effect profiles including ocular surface disease from preservatives, and psychological distress from progressive incurable disease diagnosis informing shared decision-making balancing efficacy against adverse effects.
Membership Investment
Why Publish With Us
Global Burden Prevention
Glaucoma affects over seventy million people worldwide with disproportionate impact in African and Asian populations. Our research emphasizes screening program implementation in high-risk groups including individuals with African ancestry experiencing higher prevalence and earlier onset, first-degree relatives carrying genetic susceptibility, high myopes with elongated globes predisposing to mechanical optic nerve stress, and elderly populations with age-related trabecular meshwork dysfunction enabling early case detection and treatment initiation preventing progression to irreversible blindness and improving global public health outcomes.
Adherence Optimization
Medication non-adherence substantially limits glaucoma treatment effectiveness with studies documenting only fifty percent adherence to prescribed eyedrop regimens. We publish research on adherence barriers including complex multi-drop regimens, physical difficulties instilling drops particularly in elderly arthritis patients, medication costs creating financial barriers, and asymptomatic disease nature reducing perceived treatment urgency. Interventions including reminder systems, education programs, sustained-release formulations, and combination medications improve real-world outcomes.
Pediatric Glaucoma
Childhood glaucoma presents unique diagnostic and management challenges requiring specialized expertise. Our journal publishes research on primary congenital glaucoma pathophysiology involving trabecular meshwork maldevelopment, juvenile open-angle glaucoma genetic mutations in myocilin gene, secondary glaucoma from congenital anomalies including aniridia and Sturge-Weber syndrome, examination under anesthesia techniques, surgical approaches including goniotomy and trabeculotomy addressing developmental outflow obstruction, and long-term outcome studies assessing amblyopia risk.
Artificial Intelligence Applications
Machine learning algorithms demonstrate promising performance in glaucoma diagnosis and progression detection approaching and sometimes exceeding specialist accuracy. We feature research on deep learning optic disc analysis from fundus photographs achieving diagnostic accuracy comparable to glaucoma specialists, automated visual field interpretation detecting progression patterns earlier than conventional statistical methods, OCT image segmentation, risk prediction models integrating clinical demographic and genetic variables, and telemedicine screening systems expanding access to care in underserved populations worldwide.
Preserving Vision Worldwide
The IJG research community encompasses leading academic ophthalmology departments investigating glaucoma pathophysiology and treatment innovation, comprehensive eye centers implementing multidisciplinary glaucoma care programs coordinating medical laser and surgical interventions, pharmaceutical companies developing novel pressure-lowering medications and neuroprotective therapeutics addressing pressure-independent ganglion cell loss mechanisms, medical device manufacturers engineering minimally invasive surgical technologies and advanced diagnostic platforms incorporating artificial intelligence, and international public health organizations implementing population-based screening programs in high-burden regions. Member collaboration advances glaucoma science from fundamental aqueous humor dynamics research through clinical trial validation and global guideline development improving vision preservation outcomes for millions of glaucoma patients worldwide preventing irreversible blindness through evidence-based early detection and optimal treatment strategies.
Membership Questions?
Contact our editorial team for assistance with membership and publication inquiries.
[email protected]Publish Your Vision Research
Submit your glaucoma and visual science research for expert peer review and immediate global open access distribution advancing vision preservation and improving patient outcomes worldwide.